207 related articles for article (PubMed ID: 20598596)
21. Clinical and pathological prognostic factors in canine mammary tumors.
Pérez Alenza MD; Peña L; Nieto AI; Castaño M
Ann Ist Super Sanita; 1997; 33(4):581-5. PubMed ID: 9616968
[TBL] [Abstract][Full Text] [Related]
22. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of tumour-associated macrophages in canine mammary tumours.
Raposo T; Gregório H; Pires I; Prada J; Queiroga FL
Vet Comp Oncol; 2014 Mar; 12(1):10-9. PubMed ID: 22533625
[TBL] [Abstract][Full Text] [Related]
24. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence.
Sorenmo KU; Kristiansen VM; Cofone MA; Shofer FS; Breen AM; Langeland M; Mongil CM; Grondahl AM; Teige J; Goldschmidt MH
Vet Comp Oncol; 2009 Sep; 7(3):162-72. PubMed ID: 19691645
[TBL] [Abstract][Full Text] [Related]
25. [Expression and significance of urokinase-type plasminogen activator in breast cancer].
Xiao J; Zhang G; Xia W
Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):196-8. PubMed ID: 11776834
[TBL] [Abstract][Full Text] [Related]
26. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase-9 expression in mammary gland tumors in dogs and its relationship with prognostic factors and patient outcome.
Santos AA; Lopes CC; Marques RM; Amorim IF; Gärtner MF; de Matos AJ
Am J Vet Res; 2012 May; 73(5):689-97. PubMed ID: 22533401
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of vascular endothelial growth factor in canine mammary tumours.
Santos AA; Oliveira JT; Lopes CC; Amorim IF; Vicente CM; Gärtner FR; Matos AJ
J Comp Pathol; 2010 Nov; 143(4):268-75. PubMed ID: 20570280
[TBL] [Abstract][Full Text] [Related]
29. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
[TBL] [Abstract][Full Text] [Related]
31. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
32. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
[TBL] [Abstract][Full Text] [Related]
33. Metallothionein expression in benign and malignant canine mammary gland tumours.
Erginsoy SD; Sozmen M; Caldin M; Furlanello T
Res Vet Sci; 2006 Aug; 81(1):46-50. PubMed ID: 16289156
[TBL] [Abstract][Full Text] [Related]
34. Improving the diagnosis and treatment of canine mammary tumours: Immunohistochemical markers as prognostic tools.
Morris JS
Vet J; 2010 Apr; 184(1):3-4. PubMed ID: 19713137
[No Abstract] [Full Text] [Related]
35. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
38. [Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma].
Geleţu G; Plămădeală P; Gogălniceanu D; Zeilhofer HF; Popescu E; Moscalu M
Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):79-84. PubMed ID: 15688761
[TBL] [Abstract][Full Text] [Related]
39. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
[TBL] [Abstract][Full Text] [Related]
40. Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas.
Papparella S; Restucci B; Paciello O; Maiolino P
J Comp Pathol; 2002 May; 126(4):271-6. PubMed ID: 12056775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
